Telemonitoring Cost-Benefit Cardiac Program Model

Telemonitoring Cost-Benefit Cardiac Program Model: Explanation and Clinical Context The Telemonitoring Cost-Benefit Cardiac Program Model is designed to estimate the financial impact and efficiency of implementing telemonitoring programs for patients with chronic heart failure or post–cardiac hospitalization follow-up. It combines key cost elements — baseline hospitalization cost, expected reduction in readmissions, and telemonitoring program expenses — to produce a quantitative estimation of net savings and return on investment (ROI). Concept and Formula Telemonitoring aims to reduce recurrent hospitalizations through early detection of decompensation, medication optimization, and improved adherence.

The cost-benefit model compares baseline care expenditure with projected cost reductions and new implementation costs. The formula is: Net Savings = (Baseline Cost × Reduction %) − (Telemonitoring Cost × Patients) ROI (%) = (Net Savings ÷ Telemonitoring Cost) × 100 Typical Parameters Clinical studies have reported 15–30% reductions in heart failure–related hospitalizations with structured telemonitoring, though results vary by population, adherence, and system integration. Annual telemonitoring costs may range between USD 300–800 per patient depending on the technology used (home sensors, mobile app platforms, nurse triage, or AI-based analytics).

Clinical and Economic Significance In cost-effectiveness analyses, a positive Net Savings or ROI above 0% indicates that telemonitoring provides financial benefit beyond its operational cost. Programs with ROI exceeding 20–30% are typically considered highly efficient in health economics. In heart failure management, beyond cost, telemonitoring is linked to improved quality-adjusted life years (QALY), better patient engagement, and lower all-cause mortality in some cohorts.

Clinical Interpretation Summary This model helps clinicians, hospital administrators, and policymakers assess whether a telemonitoring initiative would yield net economic benefit in a specific cardiac population. It can be adapted using real-world cost data, hospitalization rates, and national reimbursement structures for precision modeling.